Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Forecasts Loss for Fiscal 2008 After Flurry of M&A Moves

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceutical forecasted losses for fiscal year 2008 due in large part to recent M&A activity, and operating income and ordinary income fell in fiscal year 2007, the company announced
Advertisement

Related Content

Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug
Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug
Analyst Says FDA First-Line Approval Of Takeda/Millennium’s Velcade No Surprise
Analyst Says FDA First-Line Approval Of Takeda/Millennium’s Velcade No Surprise
Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
Japanese Takeda Buys Abbott’s Stake In TAP Joint U.S. Venture
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Takeda Makes $1 Billion Move For Amgen Development Rights
Takeda Makes $1 Billion Move For Amgen Development Rights
Advertisement
UsernamePublicRestriction

Register

SC068546

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel